Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis

医学 类风湿性关节炎 内科学 甲氨蝶呤 羟基氯喹 人口 随机对照试验 关节炎 胃肠病学 外科 疾病 环境卫生 传染病(医学专业) 2019年冠状病毒病(COVID-19)
作者
Daniel H. Solomon,Jon T. Giles,Katherine P. Liao,Paul M Ridker,Pamela M. Rist,Robert J. Glynn,Rachel Broderick,Fengxin Lu,Meredith Murray,Kathleen M.M. Vanni,L Santacroce,Shady Abohashem,Philip M. Robson,Zahi A. Fayad,Venkatesh Mani,Ahmed Tawakol,Joan M. Bathon
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:82 (3): 324-330 被引量:28
标识
DOI:10.1136/ard-2022-223302
摘要

Objective Recent large-scale randomised trials demonstrate that immunomodulators reduce cardiovascular (CV) events among the general population. However, it is uncertain whether these effects apply to rheumatoid arthritis (RA) and if certain treatment strategies in RA reduce CV risk to a greater extent. Methods Patients with active RA despite use of methotrexate were randomly assigned to addition of a tumour necrosis factor (TNF) inhibitor (TNFi) or addition of sulfasalazine and hydroxychloroquine (triple therapy) for 24 weeks. Baseline and follow-up 18 F-fluorodeoxyglucose-positron emission tomography/CT scans were assessed for change in arterial inflammation, an index of CV risk, measured as an arterial target-to-background ratio (TBR) in the carotid arteries and aorta. Results 115 patients completed the protocol. The two treatment groups were well balanced with a median age of 58 years, 71% women, 57% seropositive and a baseline disease activity score in 28 joints of 4.8 (IQR 4.0, 5.6). Baseline TBR was similar across the two groups. Significant TBR reductions were observed in both groups—ΔTNFi: −0.24 (SD=0.51), Δtriple therapy: −0.19 (SD=0.51)—without difference between groups (difference in Δs: −0.02, 95% CI −0.19 to 0.15, p=0.79). While disease activity was significantly reduced across both treatment groups, there was no association with change in TBR (β=0.04, 95% CI −0.03 to 0.10). Conclusion We found that addition of either a TNFi or triple therapy resulted in clinically important improvements in vascular inflammation. However, the addition of a TNFi did not reduce arterial inflammation more than triple therapy. Trial registration number NCT02374021 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
历史真相完成签到,获得积分10
刚刚
1秒前
1秒前
Lilli完成签到,获得积分10
1秒前
2秒前
2秒前
既白完成签到,获得积分20
3秒前
英姑的应助被赫江涛采纳,获得10
3秒前
ljh完成签到,获得积分20
4秒前
5秒前
5秒前
共享精神的应助被玩家666采纳,获得10
5秒前
刘欣怡发布了新的文献求助10
5秒前
无花果的应助被烦躁的黑键盘采纳,获得10
5秒前
6秒前
mm发布了新的文献求助10
6秒前
佐仙子的应助被公主抡大锤采纳,获得10
6秒前
锣大炮完成签到,获得积分10
6秒前
酷酷寻菡完成签到,获得积分10
6秒前
HY发布了新的文献求助10
6秒前
gaoleng完成签到,获得积分10
6秒前
7秒前
开心盛男发布了新的文献求助10
7秒前
zyq发布了新的文献求助30
8秒前
佩楠完成签到,获得积分10
9秒前
ljh发布了新的文献求助10
10秒前
11秒前
aaa关注了科研通微信公众号
12秒前
第四周期发布了新的文献求助10
12秒前
小萝卜完成签到,获得积分10
12秒前
脑洞疼的应助被Cold采纳,获得10
15秒前
秋风的应助被大气的半双采纳,获得10
15秒前
FashionBoy的应助被pure采纳,获得10
16秒前
16秒前
Akim的应助被胡萝卜卜采纳,获得10
16秒前
张伟发布了新的文献求助10
17秒前
17秒前
17秒前
杜华阳完成签到,获得积分10
18秒前
YunQiao发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193438
求助须知:如何正确求助?哪些是违规求助? 9579666
关于积分的说明 21866723
捐赠科研通 7793099
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560719
邀请新用户注册赠送积分活动 2484156